Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.
Employees72,000IPONov 4, 2014SIC3841HQ1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
46.1%
Operating Margin
14.2%
EBITDA Margin
23.0%
Net Margin
8.0%
OCF Margin
—
FCF Margin
12.0%
Returns on Capital
ROE
6.9%
ROA
3.2%
ROIC
5.8%
ROCE
5.5%
ROC (Greenblatt)
29.6%
3Y ROIIC
41.4%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
31.27
Forward P/E
15.68
P/E ex-NRI
13.80
Shiller P/E (CAPE)
35.81
Cash Flow Multiples
P/FCF
20.92
P/OCF
16.22
P/Owner Earnings
23.14
FCF Yield
4.82%
Enterprise Value Multiples
EV / EBIT
28.38
EV / Forward EBIT
35.75
EV / EBITDA
14.50
EV / Forward EBITDA
16.73
EV / Revenue
3.34
EV / Forward Revenue
3.74
Asset / Sales
P/S
2.51
P/B
2.16
P/Tangible Book
—
Growth-Adjusted
PEG
1.79
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.18%
Forward Dividend Yield
2.19%
3Y Dividend Growth
6.1%
Payout Ratio
0.30
5Y Yield on Cost
3.11%
Buybacks & Dilution
3Y Buyback Ratio
−0.20%
5Y Share Change
2.5%
Combined
Shareholder Yield
2.12%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.77
Gross Debt / EBITDA
3.87
Cash / Debt
0.04
Equity / Assets
0.46
Coverage
Interest Coverage
5.08
Short-Term Liquidity
Current Ratio
1.05
Quick Ratio
0.58
Cash Ratio
0.09
Composite Scores
Piotroski F-Score
7
Altman Z-Score
1.98
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-03-10
$1.05
2026-03-31
2025-12-08
$1.05
2025-12-31
2025-09-08
$1.04
2025-09-30
2025-06-09
$1.04
2025-06-30
2025-03-10
$1.04
2025-03-31
2024-12-09
$1.04
2024-12-31
2024-09-09
$0.95
2024-09-30
2024-06-10
$0.95
2024-06-28
2024-03-07
$0.95
2024-03-29
2023-12-07
$0.95
2023-12-29
10 of 46
View allDate
Transcript
Type
2026-08-06
Q3 2026 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2026-05-07
Q2 2026 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2026-03-10
Becton Dickinson and Co at Barclays Global Healthcare Conference Transcript
Conference Presentations
2026-02-09
Q1 2026 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2026-01-27
Becton Dickinson and Co Annual Shareholders Meeting Transcript
Shareholders and Annual Meetings
2025-11-06
Q4 2025 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2025-08-07
Q3 2025 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2025-05-01
Q2 2025 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2025-02-06
Q1 2025 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
2024-11-07
Q4 2024 Becton Dickinson and Co Earnings Call Transcript
Earnings Call
10 of 89
5-Step DuPont Analysis
ROE %
6.96%
×
×
Net Margin %
8.01%
×
×
Operating Margin %
14.16%
Operating Income
$3.10B
÷
Revenue
$21.92B
×
Tax Burden
0.8923
Net Income
$1.76B
÷
Pretax Income
$1.97B
×
Interest Burden
0.6343
Pretax Income
$1.97B
÷
Operating Income
$3.10B
×
Asset Turnover
0.40
÷
Revenue
$21.92B
÷
Average Total Assets
$54.75B
Begin Total Assets
$54.66B
End Total Assets
$54.84B
×
Equity Multiplier
2.17
÷
Avg Total Assets
$54.75B
÷
Avg Stockholders Equity
$25.24B
Begin Equity
$25.20B
End Equity
$25.28B